Role of rosuvastatin in current lipid-lowering therapy

• Published in: Orvosi hetilap Vol. 151; no. 35; p. 1424
• Main Authors: Abel, Tatjána, Fehér, János
• Format: Journal Article
• Language: Hungarian
• Published: Hungary 29.08.2010
• Subjects: Acute Coronary Syndrome - blood; Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - prevention & control; Atherosclerosis - blood; Atherosclerosis - drug therapy; Atherosclerosis - etiology; Atherosclerosis - prevention & control; C-Reactive Protein - drug effects; C-Reactive Protein - metabolism; Cholesterol - blood; Disease Progression; Fluorobenzenes - therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypercholesterolemia - blood; Hypercholesterolemia - complications; Hypercholesterolemia - drug therapy; Meta-Analysis as Topic; Pyrimidines - therapeutic use; Rosuvastatin Calcium; Sulfonamides - therapeutic use
• DOI: 10.1556/OH.2010.28937
• ISSN: 0030-6002

Statins are the most widely used lipid-lowering therapy. Among them, the rosuvastatin can be well tolerated and effectively helps to reach LDL-cholesterol goals in primary and secondary cardiovascular prevention. In addition, rosuvastatin reduces triglyceride and high-sensitivity C-reactive protein level and increases high-density lipoprotein (HDL) cholesterol, too. Imaging studies demonstrated that rosuvastatin therapy can not only reduce atherosclerosis progression but might induce its regression too.